ArticleFrontiers in endocrinology2025
Insights into gastric mixed adenoneuroendocrine carcinoma: a novel comparative study of clinicopathological features and survival outcomes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mixed adenoneuroendocrine carcinoma (MANEC) is a rare and histologically complex malignancy. Due to its low incidence, data on gastric MANEC (G-MANEC) are limited, and its clinicopathological characteristics and prognosis remain poorly defined. In this study, we performed a retrospective analysis of 168 G-MANEC patients and identified a median age of 64.7 years at diagnosis. Cases were classified into adenocarcinoma (AC)-predominant and neuroendocrine carcinoma (NEC)-predominant subtypes based on histological composition, with large-cell NEC accounting for 69.9% of NEC-predominant tumors. Patterns of lymph node metastasis (LNM) included involvement of either a single component (AC or NEC) or both components. Survival analysis revealed a median overall survival (OS) of 24 months, with 1-, 3-, and 5-year survival rates of 72.6%, 39.5%, and 29.7%, respectively. Univariate and multivariate analyses identified tumor size, LNM, and histological subtype as independent prognostic factors. Compared with a cohort of 328 patients with pure gastric adenocarcinoma, G-MANEC cases exhibited distinct clinicopathological features-particularly in terms of tumor size, Ki-67 index, and LNM. Collectively, these findings underscore that G-MANEC is associated with significantly poorer overall survival than that of conventional gastric adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.